The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Semaglutide , a dual GIP/GLP-1 receptor activator , alongside Surfactant , a triple GIP/GLP-1/GCG receptor modulator , are demonstrating impressive results in improving body mass and glycemic control. Furthermore, the inclusion of NAD+ , a essential